

May 20th, 12:30 PM

Anti-pPKC θ (T538) Delivery via Cell Penetrating Peptide Mimics as a Novel Treatment of Aplastic Anemia

Emrah Ilker Ozay

University of Massachusetts Amherst, eozay@mcb.umass.edu

Gabriela Gonzalez-Perez


University of Massachusetts Amherst

Joe Torres

University of Massachusetts Amherst

See next page for additional authors

Follow this and additional works at: http://escholarship.umassmed.edu/cts_retreat

 Part of the [Cancer Biology Commons](#), [Cell Biology Commons](#), [Cellular and Molecular Physiology Commons](#), [Hemic and Lymphatic Diseases Commons](#), [Immunoprophylaxis and Therapy Commons](#), [Therapeutics Commons](#), and the [Translational Medical Research Commons](#)

Emrah Ilker Ozay, Gabriela Gonzalez-Perez, Joe Torres, Gregory N. Tew, and Lisa M. Minter, "Anti-pPKC θ (T538) Delivery via Cell Penetrating Peptide Mimics as a Novel Treatment of Aplastic Anemia" (May 20, 2014). *UMass Center for Clinical and Translational Science Research Retreat*. Paper 91.

http://escholarship.umassmed.edu/cts_retreat/2014/posters/91

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.

Presenter Information

Emrah Ilker Ozay, Gabriela Gonzalez-Perez, Joe Torres, Gregory N. Tew, and Lisa M. Minter

Comments

Abstract of poster presented at the 2014 UMass Center for Clinical and Translational Science Research Retreat, held on May 20, 2014 at the University of Massachusetts Medical School, Worcester, Mass.

Creative Commons License

This work is licensed under a [Creative Commons Attribution-Noncommercial-Share Alike 3.0 License](http://creativecommons.org/licenses/by-nc-sa/3.0/).

Anti-pPKC θ (T538) Delivery *via* Cell Penetrating Peptide Mimics as a Novel Treatment of Aplastic Anemia

Emrah Ilker Ozay^{1,2,3}, Gabriela Gonzalez-Perez², Joe Torres^{1,2}, Gregory N. Tew^{1,2,3}, and Lisa M. Minter^{1,2}

¹Program in Molecular and Cellular Biology, ²Department of Veterinary and Animal Sciences, ³Department of Polymer Science and Engineering, University of Massachusetts, Amherst, MA, 01003

Contact information: eozay@mcb.umass.edu

The objective of this study is to deliver anti-pPKC θ (T538) into T cells (hPBMCs) by using cell penetrating peptide mimics (CPPMs) to neutralize PKC θ activity both *in vitro* and *in vivo*, with the eventual goal of treating aplastic anemia (AA). AA is an immune-mediated bone marrow failure disease caused by T helper type 1 (Th1) autoimmune responses, which destroy blood cell progenitors. It was previously reported that protein kinase C theta (PKC θ), expressed specifically in T cells, plays an important role in T cell signaling by mediating Th1 differentiation. Mice treated with Rottlerin, a pharmacological inhibitor of PKC θ , are rescued from the disease when PKC θ phosphorylation was inhibited. Furthermore, humanized antibodies are increasingly gaining attention as therapies. The delivery of antibodies could be achieved *via* cell penetrating peptides (CPPs), which are able to internalize cargo into cells. Here, we designed, synthesized and characterized CPPMs to increase delivery efficiency of an antibody against phosphorylated PKC θ (T538), which subsequently interfered with the function of the kinase. We designed an *in vitro* delivery method for the CPPM/Anti-pPKC θ complex then assessed T cell activation and AA disease marker expression. Also, we generated an *in vivo* humanized mouse model of AA and tested the complex for delivery and effect on survival of these mice. Altogether the results reveal that PKC θ may be an optimal target for bone marrow failure treatment and intracellular antibody delivery may represent a novel approach for AA treatment.